Murff HJ, et al. - In a propensity score-matched retrospective cohort of 84,434 veterans newly prescribed metformin or a sulfonylurea as monotherapy, researchers evaluated the link between metformin use vs sulfonylurea use and incidence cancer risk for 10 solid tumors using Cox proportional hazard regression. Clinical covariates, including hemoglobin A1C, body mass index, and antihypertensive and lipid-lowering medications, were adjusted and ICD-9-CM codes were used to identify incidence cancers. Findings revealed no link between the use of metformin and most cancers in this large cohort study accounting for time-related biases. A strong inverse link was observed between metformin and liver cancer.